TG Therapeutics Inc (NKB2.BE)
Chart Events
Performance Outlook
| Previous Close | 12.96 |
| Open | 12.95 |
| Bid | 13.35 x N/A |
| Ask | 13.61 x N/A |
| Day's Range | 12.65 - 13.60 |
| 52 Week Range | 3.35 - 13.60 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NKB2.BE
Related Research
- GlobeNewswire
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with RMS that can be administered in a one-hour infusion following the startin
- Simply Wall St.
TG Therapeutics' (NASDAQ:TGTX) investors will be pleased with their 26% return over the last five years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
- Zacks
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
TG Therapeutics (TGTX) closed at $13.20 in the latest trading session, marking a +0.61% move from the prior day.
